PUBLICATIONS

Pantelis Sarafidis Charles J Ferro Enrique Morales Alberto Ortiz Jolanta Malyszko Radovan Hojs Khaled Khazim Robert Ekart Jose Valdivielso Denis Fouque Gérard M London Ziad Massy Petro Ruggenenti Esteban Porrini Andrej Wiecek Carmine Zoccali Francesca Mallamaci Mads Hornum, SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA, Nephrology Dialysis and Tranplantation 06 February 2019

Stožer A., Hojs R., Dolenšek J. Beta Cell Functional Adaptation and Dysfunction in Insulin Resistance and the Role of Chronic Kidney Disease, Nephron, January 2019

Liad Hinden and Joseph Tam, Do Endocannabinoids Regulate Glucose Reabsorption in the Kidney? Nephron, January 11, 2019

Escasany E. Izquierdo-Lahuerta A. Medina-Gomez G. Underlying Mechanisms of Renal Lipotoxicity in Obesity, Nephron, January 9, 2019

Correia-Costa L., Azevedo A., Caldas Afonso A. Childhood Obesity and Impact on the Kidney, Nephron, October 25, 2018

Pérez-Morales R.E., del Pino M.D Valdivielso J.M. Ortiz A.Mora-Fernández C. Navarro-González J.F, Inflammation in Diabetic Kidney Disease, Nephron, October 2018

Porrini E, Warnock DG. Evaluation of Renal Function and Renal Risk in the Twenty-First Century. Nephron. 2017;136(4):261-262. doi: 10.1159/000471757.

Luis-Lima S, Porrini E. An Overview of Errors and Flaws of Estimated GFR versus True GFR in Patients with Diabetes Mellitus. Nephron. 2017;136(4):287-291. doi: 10.1159/000453531.

Praga M, Morales E. The Fatty Kidney: Obesity and Renal Disease. Nephron. 2017; 136(4): 273-276.  doi: 10.1159/000447674.

Trevisan R, Dodesini AR. The Hyperfiltering Kidney in Diabetes. Nephron. 2017;136(4):277-280.

Cortinovis M, Perico N, Remuzzi G. Should We Still Believe in Randomized Controlled Trials in Nephrology? Nephron. 2017;136(4):281-286.

Castillo-Rodriguez E1, Fernandez-Prado R, Martin-Cleary C, Pizarro-Sánchez MS, Sanchez-Niño MD, Sanz AB, Fernandez-Fernandez B, Ortiz A.
Kidney Injury Marker 1 and Neutrophil Gelatinase-Associated Lipocalin in Chronic Kidney Disease. Nephron. 2017;136(4):263-267.

Hojs R, Ekart R, Bevc S, Hojs N. Markers of Inflammation and Oxidative Stress in the Development and Progression of Renal Disease in Diabetic Patients. Nephron.  2016;133(3):159-62.

Hornum M, Feldt-Rasmussen B. Drug Dosing and Estimated Renal Function - Any Step Forward from Effersoe? Nephron. 2017;136(4):268-272.

Hornum M, Feldt-Rasmussen B. Glomerular Filtration Rate Estimation in Renal and Non-Renal Solid Organ Transplantation. Nephron. 2017;136(4):298-301.  Nephron. 2017;136(4):292-297. doi: 10.1159/000455197.

Warnock DG, Delanaye P, Glassock RJ. Risks for All-Cause Mortality: Stratified by Age, Estimated Glomerular Filtration Rate and Albuminuria. Nephron. 2017;136(4):292-297. doi: 10.1159/000455197.

D'Agati VD, Chagnac A, de Vries AP, Levi M, Porrini E, Herman-Edelstein M, Praga M. Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. Nat Rev Nephrol. 2016 Aug;12(8):453-71. doi: 10.1038/nrneph

Porrini E, Ruggenenti P, Mogensen CE, Barlovic DP, Praga M, Cruzado JM, Hojs R, Abbate M, de Vries AP; ERA-EDTA diabesity working group. Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2015;3(5):382-91.

de Vries APJ, Ruggenenti P, Ruan XZ, Praga M, Cruzado JM, Bajema IM, D'Agati VD, Lamb HJ, Pongrac Barlovic D, Hojs R, Abbate M, Rodriquez R, Mogensen CE, Porrini E;
ERA-EDTA Working Group Diabesity. Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol.
2014;2(5):417-26.
“There is enough growing insight that ectopic lipid—the accumulation of lipid in non-adipose tissue—is associated with structural and functional changes of mesangial cells, podocytes, and proximal tubular cells to propose the development of obesity related glomerulopathy as a maladapted response to hyperfiltration and albuminuria. In this Review, we discuss the emerging role of ectopic lipid (the accumulation of lipid in non-adipose tissue) from metabolically unhealthy obesity as a novel pathway of obesity-related renal disease.”
 
Porrini E, Ruggenenti P, Mogensen C-E, Pongrac Barlovic D, Praga M, Cruzado JM, Hojs R, Abbate M, de Vries APJ, for the ERA-EDTA Working Group Diabesity.
A Role for Non-Proteinuric Pathways in loss of Renal Function in patients with Type 2 DIABETES? Lancet Diabetes Endocrinol, 2015, in press.
“In this personal view we analyze a novel phenotype of renal function decline in type 2 diabetes. Largely on the basis of data in type 1 diabetes, the natural history of diabetic renal disease has been categorized in a sequence of stages: normoalbuminuria, microalbuminuria and macroalbuminuria. Progressive decline of glomerular filtration rate was thought to parallel the onset of macroalbuminuria (overt nephropathy), whereas glomerular hyperfiltration was considered a hallmark of earlier stages. Recent studies clearly demonstrated that albuminuria is a continuum and that the GFR may start to decline before progression to overt nephropathy. In addition to proteinuria, other risk factors may sustain GFR deterioration including female gender, obesity, dyslipidemia (in particular hypertriglyceridemia), hypertension and glomerular hyperfiltration. This may explain why patients with type 2 diabetes can have renal insufficiency even before the onset of overt nephropathy.”